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Background
For rapid recombinant protein production in small to
medium size volumes, transient transfection of mamma-
lian cells is still the method of choice in biotechnology
[1]. However, due to the high costs of commercially
available lipofectamines or polycationic transfection
reagents such as polyethylenimine (PEI), the most widely
used transfection reagents available present a substantial
economic bottleneck. While these reagents produce see-
mingly high transient transfection rates [2], there is still
a strong desire for transfection reagents providing both
secure and easy handling and higher recombinant pro-
tein production. As part of our commitment to excel-
lence, InVivo BioTech Services initiated a joint venture
with emp Biotech and developed a novel polycationic
reagent, named INVect, for transient transfection and
recombinant protein production in mammalian cells.
Materials and methods
Mammalian cells were cultured in CD-ACF media using
shake flasks and standard culture conditions. Cells were
transfected with 10 μg per mL of a GOI harboring plas-
mid at a cell density of 5 × 106 cells per mL in Free-
Style™ Medium (Life Technologies) with INVect to
DNA ratio of 6:1 (w/w) and PEI to DNA ration of 2:1
(w/w). Cultures were supplemented with same volume
Protein Expression Medium (Life Technologies) 2 hours
post transfection. GFP and SEAP expression took place
in 8 mL culture volume in 50 mL bioreactor tubes.
Expression of other reporter proteins were performed in
150 mL culture volume in 500 mL shake flasks. Trans-
fection efficiency was determined 24 hours post trans-
fection by counting green fluorescent positive cells using
a FACSCalibur (Becton, Dickinson and Company).
SEAP expression was determined in cell culture super-
natant on day 6 post transfection by a photometric
pNPP turn-over assay. Quantification of IgG was per-
formed by protein G affinity chromatography on day 6
post transfection. Thrombomodulin concentration was
calculated from cell culture supernatant on day 6 post
transfection by IMUBIND® Thrombomodulin ELISA Kit
(american diagnostica). His-tagged recombinant protein
was purified on day 6 post transfection by TALON®
immobilized metal affinity chromatography system.
Results
Cytotoxicity was tested over a broad range of concentra-
tions. Results demonstrate several novel synthetic poly-
mers exhibiting transfection efficiencies even higher
than common PEIs after optimized ratios of DNA-to-
polymer were applied. Transfection efficiency of INVect
was compared to PEI, currently the standard transfec-
tion reagent for transient gene expression. INVect was
found to generally give better transfection efficiencies of
greater 80% in a GFP assay (Figure 1A). Batch-to-batch
reproducibility was shown on five independent INVect
batches. Transfection results were highly consistent and
in the range of 80-90% (Figure 1B).
INVect successfully delivers genes to HEK293-F,
CHO-S and CAP-T cells as shown in a SEAP expression
system (Figure 1C). Post-transfection cell productivity
was determined under TGE manufacturing conditions.
Thrombomodulin (60 kDa) (Figure 1D), an IgG (144
kDa) (Figure 1E) and a HIS-tagged Protein of Interest
(~40 kDa) (Figure 1F) were transiently expressed using
INVect as transfection reagent and conventional 25 kDa
PEI as control. Cells were transfected with a gene of
interest harboring plasmid, with product concentration
being measured on day 6 post transfection. The use of
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Figure 1 Transfection efficiency and 6 day post-transfection cell productivity of INVect. (A) Transfection efficiency of INVect compared to
PEI. (B) transfection efficiency of 5 independent batches. Transfection efficiency was determined 24 hours post transfection by counting green
fluorescent positive CAP-T cells using a FACSCalibur (Becton, Dickinson and Company). (C) CHO-S, HEK293-F and CAP-T cells were transfected
with a SEAP harboring plasmid. Relative SEAP expression was determined in cell culture supernatant by a photometric pNPP turn-over assay. (D)
CAP-T cells were transfected with a Thrombomodulin harboring plasmid. Thrombomodulin concentration was calculated from cell culture
supernatant by IMUBIND® Thrombomodulin ELISA Kit (american diagnostica). (E) CAP-T cells were transfected with an IgG harboring plasmid.
Antibody concentration was determined by protein G affinity chromatography. (F) CAP-T cells were transfected with a His-tagged protein
harboring plasmid. Protein of interest was purified by TALON® immobilized metal affinity chromatography system.
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INVect provided a minimum 2-fold increase in protein
production over PEI (25 kDa) based transfection.
Conclusions
INVect is a novel polycationic transfection reagent
which demonstrates low cell toxicity for transient trans-
fection of mammalian cells and delivers extremely high
transfection efficiencies of up to 90%, 24 h post trans-
fection. The use of INVect for transfection under TGE
conditions leads to exceptionally high levels of protein
expression and outperforms 25 kDa linear PEI by 2-fold.
INVect can be used effectively with all common cell
lines and is especially suited for HEK293-F and CAP-T
cells.
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